Woman Gets 5-Year Drug Import Ban, Ghosts Her Own Hearing
Published Date: 11/25/2025
Notice
Summary
Nicole Shelby Randall is officially banned for 5 years from importing any drugs into the U.S. because she was convicted of bringing in a bad drug that broke federal law. She didn’t respond to the FDA’s notice or ask for a hearing, so the ban started on November 25, 2025. She can apply to end the ban anytime, but must follow special rules to keep her info private.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Five‑Year Import Ban for Nicole Randall
Nicole Shelby Randall is debarred for 5 years from importing or offering for import any drug into the United States, effective November 25, 2025. The debarment follows her January 22, 2025 felony conviction for introducing an adulterated drug into interstate commerce, and FDA states that importing drugs by, with the assistance of, or at the direction of Ms. Randall is a prohibited act.
Right to Apply and Public Filing Rules
Ms. Randall (or anyone seeking termination of debarment) may apply to end the debarment at any time under section 306(d)(1). Applications submitted electronically to https://www.regulations.gov will be posted publicly unchanged; to keep information confidential you must submit a written/paper application with two copies (one marked confidential and one redacted) to the Dockets Management Staff as described in the order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-21074 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on December 19, 2025, to review important cancer research grant applications. These meetings are private to protect secret ideas and personal info of applicants. Researchers waiting on funding decisions should note this date, but no new costs or changes to the process are announced.
Next: 2025-21076 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on January 6, 2026, to review important cancer research grant applications. These meetings are private to protect secret ideas and personal info. Scientists and researchers applying for grants should note this date, but no new costs or changes affect the public.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in